Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Intravesical therapy for overactive bladder].

J Pannek1, U Grigoleit, R Wormland

  • 1Schwerpunkt Neuro-Urologie, Urologische und Neuro-Urologische Klinik, Ruhr-Universität Bochum, Marienhospital, Herne. juergen.pannek@marienhospital-herne.de

Der Urologe. Ausg. A
|January 27, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Rehabilitation after Spinal Cord Injury : Current trends and principles].

Unfallchirurgie (Heidelberg, Germany)·2023
Same author

[Course of neurogenic bladder dysfunction in patients with spinal cord injury under homeopathic treatment].

Der Urologe. Ausg. A·2020
Same author

[Use of synthetic slings and mesh implants in the treatment of female stress urinary incontinence and prolapse : Statement of the Working Group on Urological Functional Diagnostics and Female Urology of the Academy of the German Society of Urology].

Der Urologe. Ausg. A·2019
Same author

[Erratum to: Overactive bladder-which treatment when?]

Der Urologe. Ausg. A·2018
Same author

[Overactive bladder-which treatment when?]

Der Urologe. Ausg. A·2017
Same author

The effects of antimuscarinic treatment on the cognition of spinal cord injured individuals with neurogenic lower urinary tract dysfunction: a prospective controlled before-and-after study.

Spinal cord·2017
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

For overactive bladder refractory to oral treatments, intravesical oxybutynin (86% success), EMDA (78% success), and capsaicin (47% success) offer effective alternatives to botulinum A toxin, with careful consideration of risks and benefits for each patient.

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Oral anticholinergic drugs for overactive bladder (OAB) often lack efficacy and cause side effects, leading to treatment discontinuation.
  • Botulinum A toxin is a milestone treatment for detrusor overactivity but is invasive with limited duration and unknown long-term outcomes.
  • This study explores effective local treatment alternatives for OAB refractory to oral medications.

Purpose of the Study:

  • To evaluate the efficacy and safety of intravesical oxybutynin, capsaicin instillation, and electrogalvanic stimulation with drug administration (EMDA) as treatments for refractory detrusor overactivity.

Main Methods:

  • Fifty-two patients received intravesical oxybutynin.
  • Sixteen patients underwent intravesical capsaicin instillation.
  • Twenty-eight patients were treated with EMDA.

Related Experiment Videos

Main Results:

  • Intravesical oxybutynin demonstrated an 86% success rate.
  • Capsaicin instillation achieved a 47% success rate.
  • EMDA showed a 78% success rate, with two cases of transient ischemic attacks as significant side effects.

Conclusions:

  • Intravesical oxybutynin, EMDA, and capsaicin are effective local treatment options for detrusor overactivity unresponsive to oral anticholinergics.
  • These therapies offer alternatives to botulinum A toxin, though risks and complications must be weighed.
  • Individualized patient assessment is crucial for selecting the optimal treatment strategy for refractory OAB.